// App-Quantinova.ai

BSH2020‐EP‐027 : Real‐world data from the United Kingdom on the sequencing of second generation tyrosine kinase inhibitors for the treatment of chronic phase Philadelphia chromosome‐positive chronic myeloid leukaemia

Researchers

Presenter

  • J. Byrne

Principal Investigators

  • H. Oakervee

  • G. Campbell

  • I. Amott

  • A. Goringe

  • E. Heartin

  • E. Dimitriadou

  • I. Pamphlett

  • S. Arami

  • P. Neelakantan

  • R. Frewin

  • S. Pillai

  • H. De Lavallade

  • N. C. P. Cross

  • L. Nelless

  • V. Nayar

  • M. Thompson

  • J. Ewing

Medical Centers

  • Clinical Oncology, Nottingham University Hospitals NHS, Nottingham

  • Haematology, Oxford University Hospitals NHS foundation trust, Oxford, UK

  • Clinical Oncology, Barts Health NHS Trust, London

  • Clinical Oncology, East Suffolk and North Essex NHS Foundation Trust, Colchester

  • Clinical Oncology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby

  • Clinical Oncology, Cardiff & Vale University Health Board, Cardiff

  • Clinical Oncology, Betsi Cadwaladr University Health Board, Swansea

  • Clinical Oncology

  • Pharmacy, Maidstone and Tunbridge Wells NHS Trust, Maidstone

  • Clinical Oncology, London North West University Healthcare NHS Trust, London

  • Clinical Oncology, Royal Berkshire NHS Foundation Trust, Reading

  • Clinical Oncology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester

  • Clinical haematology, University Hospitals of North Midlands NHS Trust, Stoke‐on‐Trent

  • Clinical Oncology, King's College NHS Foundation Trust, London

  • Human Development and Health, University of Southampton, Southampton

  • SVM Pharma Ltd, SVM Pharma Ltd, Fleet

  • Medical Director, Incyte Biosciences UK Ltd, Leatherhead

  • Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Ph chromosome

  • Cluster of Differentiation 206

Drug/Treatment

  • Bosutinib

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Multinational

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved